Informace o projektu
Understanding the eIF4F role in melanoma
(eIF4F in melanoma)
- Kód projektu
- MUNI/IGA/1108/2021
- Období řešení
- 1/2022 - 12/2022
- Investor / Programový rámec / typ projektu
-
Masarykova univerzita
- Interní grantová agentura MU
- Fakulta / Pracoviště MU
- Lékařská fakulta
Acquired resistance to BRAF and MEK inhibitors leads to ERK pathway reactivation and rapid disease progression in melanoma patients. Enhanced eIF4F activity is a potential therapeutic target as it was linked to the drug resistance. This project will provide new mechanistic insight into the link between eIF4F and ERK signaling in melanoma. Our findings could help to increase melanoma patient survival rates.